Free Trial

Verastem (VSTM) Stock Price, News & Analysis

-0.30 (-2.53%)
(As of 02:07 PM ET)
Today's Range
50-Day Range
52-Week Range
38,219 shs
Average Volume
135,570 shs
Market Capitalization
$293.32 million
P/E Ratio
Dividend Yield
Price Target

Verastem MarketRank™ Stock Analysis

Analyst Rating
3.00 Rating Score
148.2% Upside
$28.79 Price Target
Short Interest
3.49% of Float Sold Short
Dividend Strength
News Sentiment
Insider Trading
Selling Shares
$6,619 Sold Last Quarter
Proj. Earnings Growth
From ($4.14) to ($3.49) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.93 out of 5 stars

Medical Sector

551st out of 921 stocks

Pharmaceutical Preparations Industry

256th out of 425 stocks

VSTM stock logo

About Verastem Stock (NASDAQ:VSTM)

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.

VSTM Stock Price History

VSTM Stock News Headlines

Verastem (NASDAQ:VSTM) Raised to Hold at
VSTM Stock Earnings: Verastem Beats EPS for Q1 2024
Arrowhead Research: Fiscal Q2 Earnings Snapshot
Verastem, Inc. (VSTM)
VSTM Apr 2024 11.000 call
VSTM Apr 2024 14.000 call
Recap: Verastem Q4 Earnings
See More Headlines
Receive VSTM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Verastem and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
6 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
$2.60 million
Book Value
$0.99 per share


Free Float
Market Cap
$293.83 million
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Mr. Daniel W. Paterson (Age 63)
    President, CEO & Director
    Comp: $697.98k
  • Mr. Daniel Calkins (Age 36)
    CFO and Principal Accounting & Financial Officer
    Comp: $1.42M
  • Mr. Richard H. Aldrich M.B.A. (Age 70)
    Founder and Consultant
    Comp: $38.39k
  • Dr. Robert A. Weinberg Ph.D.
    Co-Founder & Chair of Scientific Advisory Board
  • Dr. Piyush B. Gupta Ph.D.
  • Dr. Michelle Dipp M.D. (Age 48)
    Ph.D., Co-Founder
  • Mr. Robert Pintar M.B.A.
    Senior Vice President of Technical Operations
  • Dr. Jonathan Pachter Ph.D. (Age 66)
    Chief Scientific Officer
    Comp: $238.18k
  • Mr. Nate Sanburn
    Senior Vice President of Corporate Development & External Engagement
  • Dr. Hagop Youssoufian M.D. (Age 67)
    M.Sc., Ph.D., Head of Medical Strategy

VSTM Stock Analysis - Frequently Asked Questions

Should I buy or sell Verastem stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Verastem in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" VSTM shares.
View VSTM analyst ratings
or view top-rated stocks.

What is Verastem's stock price target for 2024?

6 equities research analysts have issued 1 year price objectives for Verastem's stock. Their VSTM share price targets range from $17.50 to $36.00. On average, they expect the company's share price to reach $28.79 in the next twelve months. This suggests a possible upside of 148.2% from the stock's current price.
View analysts price targets for VSTM
or view top-rated stocks among Wall Street analysts.

How have VSTM shares performed in 2024?

Verastem's stock was trading at $8.14 on January 1st, 2024. Since then, VSTM stock has increased by 42.5% and is now trading at $11.60.
View the best growth stocks for 2024 here

When is Verastem's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024.
View our VSTM earnings forecast

How were Verastem's earnings last quarter?

Verastem, Inc. (NASDAQ:VSTM) released its quarterly earnings results on Thursday, May, 9th. The biopharmaceutical company reported ($1.26) earnings per share for the quarter, missing analysts' consensus estimates of ($1.16) by $0.10.

When did Verastem's stock split?

Shares of Verastem reverse split on Thursday, June 1st 2023. The 1-12 reverse split was announced on Thursday, June 1st 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, June 1st 2023. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

What is Robert Forrester's approval rating as Verastem's CEO?

11 employees have rated Verastem Chief Executive Officer Robert Forrester on Robert Forrester has an approval rating of 100% among the company's employees. This puts Robert Forrester in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Verastem own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Verastem investors own include TherapeuticsMD (TXMD), Micron Technology (MU), Novavax (NVAX), Inovio Pharmaceuticals (INO), Gilead Sciences (gild), Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), TG Therapeutics (TGTX), Amarin (AMRN) and Viking Therapeutics (VKTX).

Who are Verastem's major shareholders?

Verastem's stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (4.59%) and Cannon Global Investment Management LLC (0.04%). Insiders that own company stock include Brian M Stuglik, Dan Paterson, Daniel Calkins and Robert E Gagnon.
View institutional ownership trends

How do I buy shares of Verastem?

Shares of VSTM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:VSTM) was last updated on 5/23/2024 by Staff

From Our Partners